First defense for Zemiglo on 1st next month

Published: 2016-05-19 13:59:10

Updated: 2016-05-19 13:59:10

A conflict for the sales right of the LG Life Sciences’ domestic antidiabetic ‘Zemiglo’ will be handled in a courtroom.

According to the industry on the 17^th, Sanofi-Aventis Korea, the previous seller of Zemiglo, will start to process a damage suit against LG Life Sciences, the original developer, and Daewwong Pharmaceutical, the current seller, from the 1^st next month.

Zemiglo which had be...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.